International Journal of Drug Delivery Technology
Volume 14, Issue 3

Potency of Natural Compounds in Inhaled Micro/Nanoparticle for Lung Infection Therapy

Shafa Azaria1,2, Noorma Rosita2,3, Dewi Melani Hariyadi2,3,4*

1Master Programme of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia. 2Department of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Campus C Mulyorejo, Surabay, Indonesia.

3Pharmaceutics and Delivery Systems for Drugs, Cosmetics and Nanomedicine (Pharm-DCN) Research Group, Faculty of Pharmacy, Universitas Airlangga, Campus C Mulyorejo, Surabaya, Indonesia.

4Inter-University Center of Excellence (IUCoE) of Health Autonomy-Drug Discovery, Universitas Airlangga, Campus C Mulyorejo, Surabaya, Indonesia. 

Received: 20th January, 2024; Revised: 27th February, 2024; Accepted: 18th July, 2024; Available Online: 25th September, 2024 

ABSTRACT

Pulmonary infection is a disease-causing death worldwide that attacks the lower airway organs by various kinds of microorganisms. Antibacterial or antiviral has been used for the therapy of lung infections, but up to this point the case of resistance to drugs is still high. Therefore, to overcome this problem, it is necessary to develop new drugs, namely natural drugs. However, natural drugs have limitations (physicochemical properties and low bioavailability), so the development of inhalation natural drug delivery systems is needed. Various studies have been conducted to develop inhalation natural drug delivery systems such as microparticles, microsponges, nanoparticles, nanomicelles, etc. The use of these delivery systems has been shown to have a positive impact on the physico-chemical properties, bioavailability and antibiotic/antiviral activity of natural drugs through targeted delivery of lungs both in-vitro and in-vivo.

Keywords: Lung infection, Drug delivery system, Inhalation, natural materials, Microparticles, Nanoparticles. International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.3.92

How to cite this article: Azaria S, Rosita N, Hariyadi DM. Potency of Natural Compounds in Inhaled Micro/Nanoparticle for Lung Infection Therapy. International Journal of Drug Delivery Technology. 2024;14(3):1921-1930.

REFERENCES

  1. Prabhu FR, Sikes AR, Sulapas I. Family Medicine. Springer International Publishing: Cham; DOI: 10.1007/978-3-319- 04414-9.
  2. Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ, Ratjen FA.
  3. Antibiotic Management of Lung Infections in Cystic Fibrosis. II. Nontuberculous Mycobacteria, Anaerobic Bacteria, and Fungi. Annals of the American Thoracic Society 2014;11(8):1298–1306. DOI: 10.1513/AnnalsATS.201405-203AS.
  4. Cookson WOCM, Cox MJ, Moffatt MF. New opportunities for managing acute and chronic lung infections. Nature Publishing Group 2017;16(2):111–120. DOI: 1038/nrmicro.2017.122.
  5. Jaroszewski DE, Webb BJ, Leslie Diagnosis and Management of Lung Infections. Thoracic Surgery Clinics 2012;22(3):301–324. DOI: 10.1016/j.thorsurg.2012.05.002.
  6. Cilloniz C, Martin-Loeches I, Garcia-Vidal C, San Jose A, Torres
  7. Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns. International Journal of Molecular Sciences 2016;17(12):2120. DOI: 10.3390/ijms17122120.
  8. The Top 10 Causes of Death. 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10- causes-of-death.
  9. Curran CS, Bolig T, Torabi-Parizi Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection. American Journal of Respiratory and Critical Care Medicine 2018;197(6):708–727. DOI: 10.1164/rccm.201705-1043SO.
  10. World Health Organization. Bacterial Priority Pathogens List, 2024. 2024.
  11. Sadeek AM, Abdallah EM. Phytochemical Compounds as Antibacterial Agents: A Mini Review. Global Journal of Pharmacy & Pharmaceutical Sciences 2019;7(4):1–6. DOI: 19080/GJPPS.2019.07.555720.
  12. Bhagirath AY, Li Y, Somayajula D, Dadashi M, Badr S, Duan Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulmonary Medicine 2016;16(1):174. DOI: 10.1186/s12890-016-0339-5.
  13. Ciofu O, Tolker-Nielsen T, Jensen PØ, Wang H, Høiby N. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. Advanced Drug Delivery Reviews 2015;85:7–23. DOI: 1016/j. addr.2014.11.017.
  14. Behl T, Rocchetti G, Chadha S, et Phytochemicals from Plant Foods as Potential Source of Antiviral Agents: An Overview. Pharmaceuticals 2021;14(4):1–46. DOI: 10.3390/ph14040381.
  15. Majnooni MB, Fakhri S, Shokoohinia Y, Kiyani N, Stage K, Mohammadi P, Gravandi MM, Farzaei MH, Echeverría J. Phytochemicals: Potential Therapeutic Interventions Against Coronavirus-Associated Lung Frontiers in Pharmacology 2020;11(November). DOI: 10.3389/fphar.2020.588467.
  16. Khare T, Anand U, Dey A, Assaraf YG, Chen ZS, Liu Z, Kumar V. Exploring Phytochemicals for Combating Antibiotic Resistance in Microbial Pathogens. Frontiers in Pharmacology 2021;12(July):1–18. DOI: 10.3389/fphar.2021.720726.
  17. Ahmad R, Srivastava S, Ghosh S, Khare SK. Phytochemical delivery through nanocarriers: a review. Colloids and Surfaces B: Biointerfaces 2021;197(July 2020):111389. DOI: 10.1016/j. 2020.111389.
  18. Yadav H, Mahalvar A, Pradhan M, Yadav K, Kumar Sahu K, Yadav R. Exploring the potential of phytochemicals and nanomaterial: A boon to antimicrobial treatment. Medicine in Drug Discovery 2023;17(December 2022):100151. DOI: 1016/j. medidd.2023.100151.
  19. Solanki R, Jodha B, Prabina KE, Aggarwal N, Patel S. Recent advances in phytochemical based nano-drug delivery systems to combat breast cancer: A Journal of Drug Delivery
  20. Science and Technology 2022;77(June):103832. DOI: 10.1016/j. jddst.2022.103832.
  21. Chaughule RS, Barve RS. Role of herbal medicines in the treatment of infectious Vegetos 2024;37(1):41–51. DOI: 10.1007/s42535-022-00549-2.
  22. Hickey Emerging trends in inhaled drug delivery. Advanced Drug Delivery Reviews 2020;157(January):63–70. DOI: 10.1016/j. addr.2020.07.006.
  23. da Silva BA, Krishnamurthy M. The alarming reality of medication error: a patient case and review of Pennsylvania and National Journal of Community Hospital Internal Medicine Perspectives 2016;6(4):31758. DOI: 10.3402/jchimp.v6.31758.
  24. Anderson S, Atkins P, Bäckman P, et Inhaled Medicines: Past, Present, and Future. Pharmacological Reviews 2022;74(1):48–DOI: 10.1124/pharmrev.120.000108.
  25. Huang Z, Kłodzińska SN, Wan F, Nielsen HM. Nanoparticle- mediated pulmonary drug delivery: state of the art towards efficient treatment of recalcitrant respiratory tract bacterial infections. Drug Delivery and Translational Research 2021;11(4):1634–1654. DOI: 10.1007/s13346-021-00954-1.
  26. Kanojia N, Singh S, Singh J, Sharma N, Grewal AS, Rani L, Thapa K, Arora Recent Advancements and Applications of Inhalable Microparticles Based Drug Delivery Systems in Respiratory Disorders. Biointerface Research in Applied Chemistry 2020;11(3):10099–10118. DOI: 10.33263/BRIAC113.1009910118.
  27. Jain H, Bairagi A, Srivastava S, Singh SB, Mehra NK. Recent advances in the development of microparticles for pulmonary administration. Drug Discovery Today 2020;25(10):1865–1872. DOI: 10.1016/j.drudis.2020.07.018.
  28. Scherließ R, Bock S, Bungert N, Neustock A, Valentin Particle engineering in dry powders for inhalation. European Journal of Pharmaceutical Sciences 2022;172(October 2021):106158. DOI: 10.1016/j.ejps.2022.106158.
  29. Knap K, Kwiecien K, Reczynska-Kolman K, Pamula E. Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations. Regenerative Biomaterials 2023;10(December 2022). DOI: 10.1093/rb/rbac099.
  30. Praphawatvet T, Peters JI, Williams Inhaled nanoparticles– An updated review. International Journal of Pharmaceutics 2020;587(July):119671. DOI: 10.1016/j.ijpharm.2020.119671.
  31. Prestisya IA, Miatmoko A, Rahmadi M, Hariyadi Dry Powder Inhalation Microparticles (Alginate, Carrageenan, Chitosan, and Combination Polymers): A Review on Characteristics and In-vivo Activity. Egyptian Journal of Chemistry 2022;65(12):181–206. DOI: 10.21608/EJCHEM.2022.119143.5364.
  32. Dong W, Ye J, Zhou J, Wang W, Wang H, Zheng X, Yang Y, Xia X, Liu Y. Comparative study of mucoadhesive and mucus- penetrative nanoparticles based on phospholipid complex to overcome the mucus barrier for inhaled delivery of baicalein. Acta Pharmaceutica Sinica B 2020;10(8):1576–1585. DOI: 1016/j.apsb.2019.10.002.
  33. Arefin P, Habib MS, Chakraborty D, Bhattacharjee SC, Das S. An overview of microcapsule dosage International Journal of Pharmaceutical Chemistry and Analysis 2021;7(4):155–160. DOI: 10.18231/j.ijpca.2020.025.
  34. Maretti E, Rossi T, Bondi M, Croce MA, Hanuskova M, Leo E, Sacchetti F, Iannuccelli V. Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis. International Journal of Pharmaceutics 2014;462(1–2):74–82. DOI: 10.1016/j. ijpharm.2013.12.034.
  35. Jadhav N, Patel V, Mungekar S, Bhamare G, Karpe M, KadamsMicrosponge Delivery System: An updated review, current status and future prospects. Journal of Scientific and Innovative Research 2013;2(6):1097–1110.
  36. Alexescu T, Tarmure S, Negrean V, Cosnarovici M, Ruta V, Popovici I, Para I, Perne M, Orasan O, Todea D. Nanoparticles in the treatment of chronic lung diseases. Journal of Mind and Medical Sciences 2019;6(2):224–231. DOI: 10.22543/7674.62.
  37. Liu Q, Guan J, Qin L, Zhang X, Mao S. Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery. Drug Discovery Today 2020;25(1):150–159. DOI: 1016/j.drudis.2019.09.023.
  38. Virmani R, Pathak K. Targeted Polymeric Micellar Systems for Respiratory Diseases. In: Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems Elsevier; 2020; 411–439. DOI: 10.1016/B978-0-12-820658-4.00020-0.
  39. Sai T, Fujita K. A review of pulmonary toxicity studies of Inhalation Toxicology 2020;32(6):231–239. DOI: 10.1080/08958378.2020.1770901.
  40. Kupnik K, Primožič M, Kokol V, Leitgeb M. Nanocellulose in Drug Delivery and Antimicrobially Active Materials. Polymers 2020;12(12):2825. DOI: 10.3390/polym12122825.
  41. Leong EWX, Ge R. Lipid Nanoparticles as Delivery Vehicles for Inhaled Therapeutics. Biomedicines 2022;10(9):2179. DOI: 3390/biomedicines10092179.
  42. Zheng D, Huang C, Huang H, Zhao Y, Khan MRU, Zhao H, Huang L. Antibacterial Mechanism of Curcumin: A Review. Chemistry and Biodiversity 2020;17(8). DOI: 10.1002/ 202000171.
  43. Fu YS, Chen TH, Weng L, Huang L, Lai D, Weng CF. Pharmacological properties and underlying mechanisms of curcumin and prospects in medicinal potential. Biomedicine and Pharmacotherapy 2021;141(June):111888. DOI: 10.1016/j. 2021.111888.
  44. Hegde M, Girisa S, BharathwajChetty B, Vishwa R, Kunnumakkara Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far? ACS Omega 2023;8(12):10713–10746. DOI: 10.1021/acsomega.2c07326.
  45. Gayathri K, Bhaskaran M, Selvam C, Thilagavathi Nano formulation approaches for curcumin delivery- a review. Journal of Drug Delivery Science and Technology 2023;82(March):104326. DOI: 10.1016/j.jddst.2023.104326.
  46. Yang D, Wang T, Long M, Li P. Quercetin: Its Main Pharmacological Activity and Potential Application in Clinical Medicine. Oxidative Medicine and Cellular Longevity 2020;2020. DOI: 10.1155/2020/8825387.
  47. Nguyen TLA, Bhattacharya D. Antimicrobial Activity of Quercetin: An Approach to Its Mechanistic Molecules 2022;27(8):2494. DOI: 10.3390/molecules27082494.
  48. Mallya R, Patil Recent Developments in Formulation Design of a Multifunctional Phytochemical Quercetin: A Review. Pharmacognosy Reviews 2021;15(29):32–46. DOI: 10.5530/ phrev.2021.15.4.
  49. Di Petrillo A, Orrù G, Fais A, Fantini MC. Quercetin and its derivates as antiviral potentials: A comprehensive review. Phytotherapy Research 2022;36(1):266–278. DOI: 10.1002/ 7309.
  50. Vestergaard M, Ingmer Antibacterial and antifungal propertiesof resveratrol. International Journal of Antimicrobial Agents 2019;53(6):716–723. DOI: 10.1016/j.ijantimicag.2019.02.015.
  51. Filardo S, Di Pietro M, Mastromarino P, Sessa R. Therapeutic potential of resveratrol against emerging respiratory viral infections. Pharmacology and Therapeutics 2020;214:107613. DOI: 10.1016/j.pharmthera.2020.107613.
  52. Robertson I, Wai Hau T, Sami F, Sajid Ali M, Badgujar V, Murtuja S, Saquib Hasnain M, Khan A, Majeed S, Tahir AnsariThe science of resveratrol, formulation, pharmacokinetic barriers and its chemotherapeutic potential. International Journal of Pharmaceutics 2022;618(April):121605. DOI: 10.1016/j. ijpharm.2022.121605.
  53. Lee J, Lee DG. Novel Antifungal Mechanism of Resveratrol: Apoptosis Inducer in Candida albicans. Current Microbiology 2015;70(3):383–389. DOI: 10.1007/s00284-014-0734-1.
  54. Rodríguez-Flores EM, Mata-Espinosa D, Barrios-Payan J, Marquina-Castillo B, Castañón-Arreola M, Hernández-Pando A significant therapeutic effect of silymarin administered alone, or in combination with chemotherapy, in experimental pulmonary tuberculosis caused by drug-sensitive or drug-resistant strains: In-vitro and in-vivo studies. PLOS ONE 2019;14(5):e0217457. DOI: 10.1371/journal.pone.0217457.
  55. Antika LD, Dewi RM. The Pharmacological Properties of Silymarin and Its Constituents. Natural Product Sciences 2021;27(2):68–77. DOI: 10.20307/nps.2021.27.2.68.
  56. Di Costanzo A, Angelico R. Formulation Strategies for Enhancing the Bioavailability of Silymarin: The State of the Molecules 2019;24(11):2155. DOI: 10.3390/molecules24112155.
  57. Palit P, Mukhopadhyay A, Chattopadhyay Phyto‐ pharmacological perspective of Silymarin: A potential prophylactic or therapeutic agent for <scp>COVID</scp> ‐19, based on its promising immunomodulatory, anti‐coagulant and antiviral property. Phytotherapy Research 2021;35(8):4246–4257. DOI: 10.1002/ptr.7084.
  58. Hao S, Yang D, Zhao L, et al. EGCG-Mediated Potential Inhibition of Biofilm Development and Quorum Sensing in Pseudomonas aeruginosa. International Journal of Molecular Sciences 2021;22(9):4946. DOI: 10.3390/ijms22094946.
  59. Mehmood S, Maqsood M, Mahtab N, Khan MI, Sahar A, Zaib S, Gul S. Epigallocatechin gallate: Phytochemistry, bioavailability, utilization challenges, and strategies. Journal of Food Biochemistry 2022;46(8):1–27. DOI: 1111/jfbc.14189.
  60. Zhang Z, Zhang X, Bi K, He Y, Yan W, Yang CS, Zhang J. Potential Protective Mechanisms of Green Tea Polyphenol EGCG against COVID-19. Trends in Food Science and Technology 2021;114(January):11–24. DOI: 1016/j.tifs.2021.05.023.
  61. Mokra D, Adamcakova J, Mokry Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate (EGCG): A Time for a New Player in the Treatment of Respiratory Diseases? Antioxidants 2022;11(8):1566. DOI: 10.3390/antiox11081566.
  62. Kalalo T, Miatmoko A, Tanojo H, Erawati T, Hariyadi DM, Rosita N. Effect of Sodium Alginate Concentration on Characteristics, Stability and Drug Release of Inhalation Quercetin Microspheres. JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA 2022;9(2):107–114. DOI: 20473/jfiki.v9i22022.107-114.
  63. El-Sherbiny IM, Smyth HDC. Controlled Release Pulmonary Administration of Curcumin Using Swellable Biocompatible Microparticles. Molecular Pharmaceutics 2012;9(2):269–280. DOI: 10.1021/mp200351y.
  64. Lababidi N, Montefusco-Pereira CV, de Souza Carvalho-WodarzC, Lehr CM, Schneider M. Spray-dried multidrug particles for pulmonary co-delivery of antibiotics with N-acetylcysteine and curcumin-loaded PLGA-nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 2020;157:200–210. DOI: 10.1016/j.ejpb.2020.10.010.
  65. Yang J, Liu C, Quan L, Liao Preparation and In-vitro Aerosol Performance of Spray-Dried Shuang-Huang-Lian Corrugated Particles in Carrier-Based Dry Powder Inhalers. AAPS PharmSciTech 2012;13(3):816–825. DOI: 10.1208/s12249-012- 9806-3.
  66. Mali AJ, Rokade A, Kamble R, Pawar A, Bothiraja Resveratrol-Loaded Microsponge as a Novel Biodegradable Carrier for Dry Powder Inhaler: A New Strategy in Lung Delivery. BioNanoScience 2021;11(1):32–43. DOI: 10.1007/ s12668-020-00800-7.
  67. Sharma A, Vaghasiya K, Ray E, Gupta P, Gupta UD, Singh AK, Verma Targeted Pulmonary Delivery of the Green Tea Polyphenol Epigallocatechin Gallate Controls the Growth of Mycobacterium tuberculosis by Enhancing the Autophagy and Suppressing Bacterial Burden. ACS Biomaterials Science and Engineering 2020;6(7):4126–4140. DOI: 10.1021/ acsbiomaterials.0c00823.
  68. Galdopórpora JM, Martinena C, Bernabeu E, et al. Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In-vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy. Pharmaceutics 2022;14(5). DOI: 10.3390/pharmaceutics14050959.
  69. Viswanathan V, Mehta H, Pharande R, Bannalikar A, Gupta P, Gupta U, Mukne A. Mannosylated gelatin nanoparticles of licorice for use in tuberculosis: Formulation, in-vitro evaluation, in-vitro cell uptake, in-vivo pharmacokinetics and in-vivoanti-tubercular efficacy. Journal of Drug Delivery Science and Technology 2018;45(January):255–263. DOI: 10.1016/j. jddst.2018.01.017.
  70. Sampath TM, Yern UG, Ching C. Enhanced curcumin loaded nanocellulose : a possible inhalable nanotherapeutic to treat COVID-19. Cellulose 2022;29(3):1821–1840. DOI: 10.1007/ s10570-021-04391-8.
  71. Fang J-Y, Huang K-Y, Wang T-H, Lin Z-C, Chen C-C, Chang S-Y, Chen E-L, Chao T-L, Yang S-C, Yang P-C, Chen C-Y. Development of nanoparticles incorporated with quercetin and ACE2-membrane as a novel therapy for COVID-19. Journal of Nanobiotechnology 2024;22(1):169. DOI: 1186/s12951-024- 02435-2.
  72. Toledo C, Gambaro RC, Padula G, Vela ME, Castro GR, Chain CY, Islan Binary Medical Nanofluids by Combination of Polymeric Eudragit Nanoparticles for Vehiculization of Tobramycin and Resveratrol: Antimicrobial, Hemotoxicity and Protein Corona Studies. Journal of Pharmaceutical Sciences 2021;110(4):1739–1748. DOI: 10.1016/j.xphs.2021.01.005.
  73. Hanafy NAN, El-Kemary MA. Silymarin/curcumin loaded albumin nanoparticles coated by chitosan as muco-inhalable delivery system observing anti-inflammatory and anti COVID-19 characterizations in oleic acid triggered lung injury and in-vitro COVID-19 experiment. International Journal of Biological Macromolecules 2022;198(January):101–110. DOI: 10.1016/j. 2021.12.073.
  74. Zhao Y, Chang YX, Hu X, Liu CY, Quan LH, Liao Solid lipid nanoparticles for sustained pulmonary delivery of Yuxingcao essential oil: Preparation, characterization and in-vivo evaluation. International Journal of Pharmaceutics 2017;516(1–2):364–371. DOI: 10.1016/j.ijpharm.2016.11.046.